Untitled Page

   Clinical Research Support | Departments | Trials | Frequently Asked Questions | Request Trial Information

 

Clinical Trial Listing

001: FOR MORE INFORMATION ON ANY OF THESE TRIALS PLEASE CALL 504-842-4481 
Call 504-842-4481 to reach the main line for the Ochsner Cancer Institute Clinical Trials Department. Leave a message with a summary of your diagnosis and/or trial interests and we will call you back as soon as possible
 
2012.103.A - Arthralgia induced by AIs and the Effects of Subcutaneous Testosterone 

Testosterone may help relieve moderate or severe arthralgia associated with the use of aromatase inhibitors, such as anastrozole or letrozole. This randomized phase III trial studies testosterone to see how well it works compared to placebo in treating postmenopausal patients with arthralgia caused by anastrozole or letrozole.


 
2012.160.A - Chemo-Inducted Nausea and Vomiting and the Effects of IV Fosaprepitant Dimeglumine 

This study aims to demonstrate that, when given concomitantly with a 5-hydroxytryptamine 3 (5-HT3) antagonist and a corticosteroid, a single 150 mg intravenous (IV) dose of fosaprepitant given on Day 1 is superior to the control regimen of 5-HT3 and corticosteroid only, in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC).

 
2013.091.A - Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy 
This randomized phase III trial is studying how well acupressure wristbands work with or without standard care in controlling nausea in young patients receiving highly emetogenic chemotherapy.
 
2013.178.A - Stage I-III Breast Cancer and Detecting Genetic Predictors for Musculoskeletal Symptoms Cause by Anastrozole 
This pilot clinical trial studies anastrozole in treating aromatase inhibitor musculoskeletal symptoms in female patients with stage I-III breast cancer. Anastrozole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
 
2013.274.C - Esophageal Cancer and the effects of PET Scan-Directed Combined Modality Therapy 

PET scans done during chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment.

This randomized phase II trial is studying PET scan imaging in assessing response in patients with esophageal cancer receiving combination chemotherapy.

 

 
SIGNITURE Module 5: PTCH1 or SMO Mutated Tumors and the Effect of LDE225 

The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study

 

 

Search by Keyword

Request Trial Information

NIH Logo

Ochsner Specialty Research Locations

Browse by Subject

Browse by Location

menu top
Left Menu Home Small
Left Menu CTU Small
Left Menu Leadership Small
Left Menu Give Small
Left Menu Contact Small
Left Menu UQ
menu bottom
Untitled Page